BIOGEN HIRLULOG LOWER INCIDENCE OF BLEEDING COMPLICATIONS v. HEPARIN IS DEEMED INSUFFICIENT CLINICAL RESULT; FIRM REDEPLOYING RESOURCES TO BETA INTERFERON
Executive Summary
A lower incidence of bleeding complications for Biogen's Hirulog compared to heparin following angioplasty was not enough of a clinical result to convince Biogen to continue developing the synthetic leech protein derivative hirudin. Cambridge, Mass.-based Biogen announced Oct. 31 that it is abandoning Hirulog following a preliminary review of Phase III trial results.